We found that ICBs therapy could upregulate CD73 expression in malignant cells via TNF-α/NF-κB signaling and adenosine produced by CD73 activated AKT/GSK3β/β-catenin signaling axis in iCCA cells. This evidence concerns the gene AKT1 and infantile convulsions and choreoathetosis.